Binimetinib

• Background :

  Binimetinib (606143-89-9) is a potent (IC50 = 12 nM) and selective allosteric inhibitor of MEK1/2.1,2 Recently approved by the FDA for treatment of melanoma in combination with Encorafenib. Binimetinib has had limited success as monotherapy but has shown promise in combination with other chemotherapeutic agents.3-5

• Conjugation :

  Unconjugated

• Buffer :

  White solid

• Storage Conditions :

  -20°C